Are Your Stem Cells Too Old to Heal? The Science Says No.
If you’ve been researching regenerative medicine, you’ve likely encountered clinics suggesting that your own stem cells are too old to be effective — and that “younger donor cells” are a superior option. It’s a compelling sales pitch. It’s also not supported by the evidence.
Do Stem Cells Change With Age?
Yes. Like all cells, stem cells are affected by aging. The total number of stem cells in bone marrow and fat tissue decreases over time, and some functional changes occur at the cellular level. This is real biology, not marketing fiction.
But here’s what the same research also shows: your own living stem cells, even in your 50s, 60s, and 70s, retain meaningful healing potential. The decrease in quantity doesn’t eliminate clinical utility — and no commercial donor product comes close to matching what your own living cells can do.
What a 20-Year Study Actually Found
Dr. Philippe Hernigou, widely regarded as one of the foundational researchers in orthobiologics, followed patients for over 20 years who received bone marrow–derived stem cell therapy for hip osteonecrosis. His findings are instructive.
Even in older patients, their own live bone marrow cells produced long-term healing outcomes. Patients treated with autologous bone marrow stem cells had better hip joint survival and lower rates of eventual joint replacement compared to control groups — across age brackets. When stem cell concentration by age group was analyzed, patients over 50 had fewer cells per mL than younger patients, but continued to show clinical benefit.
A separate 15-year knee arthritis study found that at the end of the follow-up period, the bone marrow group showed fewer than 5% complication rates compared to over 25% in the knee replacement group — and when patients were asked which treatment they preferred, 46 chose bone marrow versus 14 who preferred their knee replacement.
The data point isn’t that older cells perform identically to younger cells. It’s that your own living cells, at any reasonable adult age, outperform the alternative being marketed to you.
The Problem with “Young Donor Cells”
Commercial allogeneic products — derived from amniotic fluid, placental tissue, or umbilical cord — are frequently marketed as containing “young” or “living” stem cells with superior potency. The regulatory and scientific reality is different.
By the time donor tissue is collected, tested for infectious disease, processed, preserved, packaged, stored, and shipped, any living stem cells that may have been present are gone. What remains are growth factors and cytokines — which have genuine biological value — but not living stem cells, regardless of what the label implies. The FDA has issued warnings in this area, and the clinical evidence for superiority of these products over autologous cells simply doesn’t exist.
At Albano Clinic, we’ve tested many of these products. The literature and our own clinical experience arrive at the same conclusion.
Why Your Own Cells Are the Right Starting Point
Autologous cells — harvested from your own blood, fat, or bone marrow on the day of your procedure — are alive at the time of injection. They are a perfect genetic match with no rejection risk. And they carry the full biological signaling capacity of living tissue.
The number of cells matters less than their viability and precision of delivery. A smaller concentration of living, active cells placed accurately under ultrasound guidance into the target tissue will outperform a larger volume of processed, non-living donor material every time.
Don’t let anyone convince you that your body has aged out of its own healing potential. That’s not what the science shows — and it’s not what we see clinically.